Company Profile

LYSOGENE is a biotechnology company specializing in the research and development of gene therapies for the treatment of rare neurodegenerative diseases. The company now has 2 drug candidates in clinical development of which 1 in phase 2/3 (LYS-SAF302 for the treatment of Sanfilippo syndrome type A) and 1 in phase 1/2 (LYS-GM101 for the treatment of GM1 gangliosidosis).

Employees

Sector

Biotechnology & Medical Research

More about the company

06/23/06	Lysogene S.A.(ENXTPA:LYS) dropped from CAC AllShares Index	CI
06/23/06	Lysogene S.A.(ENXTPA:LYS) dropped from Next Biotech Index	CI
14/23/14	Lysogene CFO Assumes Same Role at Mauna Kea Technologies	MT
29/23/29	Lysogene: placed in liquidation and delisted
29/23/29	Lysogene to Delist from Euronext amid Judicial Liquidation	MT
29/23/29	Lysogene S.A. Announces Postponement of 2022 Financial Results Release	CI
17/23/17	Lysogene: no takeover bid received for biotech company
17/23/17	Lysogene Fails to Secure Takeover Bid Amid Reorganization	MT
27/23/27	Lysogene: deadline for takeover bids extended
06/23/06	Lysogene: interim CFO confirmed
06/23/06	French Gene Therapy Group Lysogene Makes Ad Interim CFO Permanent	MT
03/23/03	Lysogene Appoints Côme de La Tour du Pin as Chief Financial Officer	CI
25/23/25	Lysogene: company placed in receivership

10/23/10	Fragile X Syndrome Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)	AQ
18/23/18	Fragile X Syndrome Pipeline, Clinical Trials and NDA Approvals 2023 (Updated)	AQ
29/23/29	LYSOGENE : Inside Information / News release on accounts, results	PU
07/22/07	LYSOGENE : Inside Information / Operations of the issuer (acquisitions, sales...)	PU
30/22/30	Lysogene : Announces Favorable DSMB Review Recommending Study Continuation and Positive Biomarker Data in Stage 1 of Adaptative Clinical Trial with LYS-GM101 Gene Therapy in GM1 Gangliosidosis	PU

14/23/14	Mauna Kea Technologies : A suivre aujourd'hui
13/23/13	Mauna Kea Technologies : Côme de La Tour du Pin (ex-Lysogene) nommé Directeur financier
29/23/29	Lysogene : placé en liquidation et retiré de la cote
16/23/16	Lysogène: audience le 23 mai sur une possible liquidation judiciaire
02/23/02	Lysogene : reporte la publication de ses résultats et envisage une liquidation judiciaire

Manager	Title	Age	Since
Karen Pignet-Aiach CEO	Chief Executive Officer	54	09/05/2014
Côme de La Tour du Pin DFI	Director of Finance/CFO	-	01/11/2022
Marie Trad CTO	Chief Tech/Sci/R&D Officer	-	01/02/2022

Director	Title	Age	Since
Karen Pignet-Aiach CHM	Chairman	54	22/05/2019
Peter Lichtlen BRD	Director/Board Member	58	01/04/2018
Carole Deffez BRD	Director/Board Member	-	26/09/2019

LYSOGENE Share Price

Stocks

LYS

FR0013233475

Biotechnology & Medical Research

Latest news: LYSOGENE

Press Releases: LYSOGENE

News in other languages: LYSOGENE

Managers and Directors: LYSOGENE

Bio Diagnostics & Testing

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LYSOGENE	-.--%	-.--%	-	-	55.26L
IOVANCE BIOTHERAPEUTICS, INC.	+5.99%	+7.78%	+409.43%	+136.32%	461.58Cr
ADAPTIVE BIOTECHNOLOGIES CORPORATION	+6.02%	+3.57%	+130.66%	+482.09%	445.11Cr
VERACYTE, INC.	+10.77%	+19.65%	+48.53%	+116.02%	352.27Cr
CAREDX, INC.	+13.00%	+13.06%	+307.50%	+703.27%	280.97Cr
BGI GENOMICS CO., LTD.	+2.50%	+22.28%	-7.77%	-15.52%	251.77Cr
FREENOME, INC.	+1.97%	+6.59%	+48.11%	-	168.69Cr
SEEGENE, INC.	-0.58%	+4.78%	+29.52%	+61.14%	113.42Cr
MARAVAI LIFESCIENCES HOLDINGS, INC.	+3.80%	+5.23%	+181.25%	-17.74%	109.81Cr
CURIOX BIOSYSTEMS CO., LTD	+5.08%	+4.75%	-20.77%	+84.39%	62Cr
Average	+4.20%	+4.66%	+125.16%	+193.75%	249.57Cr
Weighted average by Cap.	+5.97%	+4.96%	+168.63%	+251.43%